Casper van Olden1, Albert K Groen2, Max Nieuwdorp3. 1. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands; Department of Pediatrics, Laboratory of Metabolic Diseases, University of Groningen, UMCG, Groningen, the Netherlands. 3. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands; VUmc Diabetes Center, Department of Internal Medicine, Free University Medical Center, Amsterdam, the Netherlands; Wallenberg Laboratory, University of Gothenberg, Gothenberg, Sweden. Electronic address: m.nieuwdorp@amc.uva.nl.
Abstract
PURPOSE: The contribution of intestinal bacterial strains (gut microbiota) in human metabolism and obesity is being increasingly recognized. The goal of this article was to provide a commentary on the clinical usefulness of these data. METHODS: We performed a review of the currently available articles on PubMed. FINDINGS: Because most of the data are based on germ-free animal research, translation to human disease may be difficult. However, changes in the intestinal bacterial composition and subsequent altered diversity have been associated with the presence of chronic low-grade inflammation, a known feature of insulin resistance and type 2 diabetes mellitus. IMPLICATIONS: It is still not proven whether intestinal bacteria play a causal role in glucose and lipid metabolism. Intervention studies including fecal transplantation and supplementation of single bacterial strains in humans might provide more insight. Moreover, prospective cohorts of healthy subjects using fecal samples collected at baseline can help to identify causally involved specific intestinal bacterial strains that drive aberrant human metabolism. Ultimately, it would be a great asset if potential diagnostic and therapeutic targets could be derived from this novel player in human cardiometabolism.
PURPOSE: The contribution of intestinal bacterial strains (gut microbiota) in human metabolism and obesity is being increasingly recognized. The goal of this article was to provide a commentary on the clinical usefulness of these data. METHODS: We performed a review of the currently available articles on PubMed. FINDINGS: Because most of the data are based on germ-free animal research, translation to human disease may be difficult. However, changes in the intestinal bacterial composition and subsequent altered diversity have been associated with the presence of chronic low-grade inflammation, a known feature of insulin resistance and type 2 diabetes mellitus. IMPLICATIONS: It is still not proven whether intestinal bacteria play a causal role in glucose and lipid metabolism. Intervention studies including fecal transplantation and supplementation of single bacterial strains in humans might provide more insight. Moreover, prospective cohorts of healthy subjects using fecal samples collected at baseline can help to identify causally involved specific intestinal bacterial strains that drive aberrant human metabolism. Ultimately, it would be a great asset if potential diagnostic and therapeutic targets could be derived from this novel player in human cardiometabolism.
Authors: Feng-Yi Yuan; Min Zhang; Ping Xu; Dan Xu; Ping Chen; Min Ren; Qin Sun; Jing-Yan Chen; Juan Du; Xia-Lian Tang Journal: Exp Ther Med Date: 2018-09-03 Impact factor: 2.447
Authors: Felipe Pinheiro de Oliveira; Roberta Hack Mendes; Priscila Thiago Dobbler; Volker Mai; Victor Salter Pylro; Sheldon G Waugh; Filippo Vairo; Lilia Farret Refosco; Luiz Fernando Würdig Roesch; Ida Vanessa Doederlein Schwartz Journal: PLoS One Date: 2016-06-23 Impact factor: 3.240